FDA Grants Fast Track Designation to Promising EBS Treatment
BioMendics has received FDA Fast Track Designation for their investigational gel treatment, BM-3103 (TolaSure® Gel™) for Epidermolysis Bullosa Simplex (EBS).
What is Fast Track Designation?
Fast Track Designation is granted to therapies targeting serious conditions with unmet medical needs. It gives BioMendics more frequent communication with the FDA, enhanced regulatory guidance, and eligibility for Rolling Review — meaning the FDA can evaluate completed sections of their application as they come in, rather than waiting for everything at once. Combined with the Orphan Drug and Rare Pediatric Disease designations BM-3103 already holds, this puts the treatment on an accelerated path toward potential approval.
The TAMES-02 Clinical Trial
BioMendics is actively conducting the TAMES-02 Phase 2 clinical trial in collaboration with researchers at Northwestern University Feinberg School of Medicine and Stanford University School of Medicine. The trial is evaluating how BM-3103 performs in people with EBS, with a focus on blister burden, pain, itch, and quality of life outcomes. They are recruiting participants!
Learn more about the TAMES-02 Clinical Trial and get involved
Brett Kopelan, Executive Director of debra of America, shared: "Families affected by EBS face daily challenges that can profoundly impact quality of life. The FDA's Fast Track Designation for BM-3103 highlights the importance of advancing promising investigational therapies and underscores the urgent need for innovation in rare genetic disorders that manifest in the skin."
debra will continue to track this research and keep our community updated as it progresses!